Transgene (company) (original) (raw)

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer. The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development. Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange.